Status:
COMPLETED
Post-fracture Medication and Mortality
Lead Sponsor:
National Cheng-Kung University Hospital
Conditions:
Osteoporosis
Osteoporosis Fracture
Eligibility:
All Genders
Brief Summary
Osteoporotic fracture is a common public-health problem in the whole world. Although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent. T...
Detailed Description
Osteoporotic fracture has become a serious health and economic burden as life expectancy increases. In a WHO report, the burden of osteoporotic fractures in 2002 was 2.8 million disability-adjusted li...
Eligibility Criteria
Inclusion
- Newly diagnosed osteoporosis and hip fracture are defined as a claim record from the NHIRD between 2009 and 2017.
Exclusion
- Patients with a diagnosis of osteoporosis or osteoporotic fractures in 2008 or before were excluded.
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
216155 Patients enrolled
Trial Details
Trial ID
NCT05366621
Start Date
November 1 2020
End Date
October 31 2021
Last Update
April 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Family Medicine, National Cheng Kung Univ Hosp
Tainan, Taiwan